moxifloxacin has been researched along with novobiocin in 15 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (novobiocin) | Trials (novobiocin) | Recent Studies (post-2010) (novobiocin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 2,271 | 15 | 290 |
| Protein | Taxonomy | moxifloxacin (IC50) | novobiocin (IC50) |
|---|---|---|---|
| DNA gyrase subunit B | Mycolicibacterium smegmatis MC2 155 | 0.046 | |
| DNA gyrase subunit B | Staphylococcus aureus | 0.0474 | |
| DNA gyrase subunit B | Streptococcus pneumoniae TIGR4 | 0.037 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 0.1441 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.1537 | |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | 7.9 | |
| DNA gyrase subunit B | Mycolicibacterium smegmatis | 0.161 | |
| DNA gyrase subunit A | Staphylococcus aureus | 0.0383 | |
| DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | 0.0446 | |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | 0.1315 | |
| DNA topoisomerase | Streptococcus pneumoniae | 2.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bobesh, KA; Jeankumar, VU; Renuka, J; Shruti, SK; Sridevi, JP; Sriram, D; Yogeeswari, P | 1 |
| Babu, KS; Jeankumar, VU; Reddy, KI; Renuka, J; Shravan, M; Sridevi, JP; Srihari, K; Sriram, D; Yogeeswari, P | 1 |
| Balakrishnan, G; Bhat, J; Chatterji, M; Dinesh, N; Ghorpade, S; Gorai, G; Guptha, S; Humnabadkar, V; Iyer, PS; Jena, LK; Kaur, P; Khadtare, P; Naik, M; Nandishaiah, R; Narayan, A; Naviri, LK; Panda, M; Ramachandran, V; Sharma, S | 1 |
| Brindha Devi, P; Janupally, R; Jeankumar, VU; Kulkarni, P; Medepi, B; Sriram, D; Suryadevara, P; Yogeeswari, P | 1 |
| Kulkarni, P; Medapi, B; Medishetti, R; Renuka, J; Saxena, S; Sridevi, JP; Sriram, D; Yogeeswari, P | 1 |
| Medapi, B; Renuka, J; Sridevi, JP; Sriram, D; Suryadevara, P; Yogeeswari, P | 1 |
| Arya, A; Bevan, D; Carter, N; Chamberlain, B; Cross, J; Daniel, A; Dolle, RE; Epie, F; Kumar, V; Lippa, B; Metcalf, CA; Moy, T; Nguyen, K; Poutsiaka, KM; Romero, JA; Ryan, D; Shotwell, J; Silverman, J; Wang, B; Wu, Y; Yang, Q; Zhang, J | 1 |
| Bobesh, KA; Kulkarni, P; Renuka, J; Srilakshmi, RR; Sriram, D; Yellanki, S; Yogeeswari, P | 1 |
| Kulkarni, P; Meda, N; Medapi, B; Sriram, D; Yogeeswari, P | 1 |
| Domalaon, R; Gorityala, BK; Goswami, S; Idowu, T; Lyu, Y; Schweizer, F; Shan, A; Yang, X; Zhanel, GG | 1 |
| Charrier, C; Cooper, IR; Kerr, WJ; Lindsay, DM; Maclean, J; McGarry, DH; Moyo, E; Pichowicz, M; Ratcliffe, AJ; Salisbury, AM; Savage, VJ; Smith, A; Stokes, NR; Walker, R; Warrilow, CE | 1 |
| Gutmann, L; Lamour, V; Moras, D; Sifaoui, F; Varon, E | 1 |
15 other study(ies) available for moxifloxacin and novobiocin
| Article | Year |
|---|---|
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium leprae | 2008 |
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
Topics: Anti-Bacterial Agents; DNA Gyrase; Drug Design; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitrogen; Piperidines; Protein Structure, Tertiary; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzofurans; Cell Line; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
Topics: | 2014 |
Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors of Staphylococcus aureus.
Topics: Animals; DNA Gyrase; Furans; Humans; Models, Molecular; Pyrroles; Staphylococcal Infections; Staphylococcus aureus; Thiophenes; Topoisomerase II Inhibitors; Zebrafish | 2015 |
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
Topics: Animals; Anti-Bacterial Agents; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium smegmatis; Mycobacterium tuberculosis; Piperidines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Zebrafish | 2015 |
4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
Topics: Aminoquinolines; Antitubercular Agents; DNA Gyrase; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2015 |
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
Topics: | 2015 |
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
Topics: Animals; Antitubercular Agents; Atrioventricular Block; Cardiotoxicity; DNA Gyrase; Enzyme Assays; Ether-A-Go-Go Potassium Channels; Heart Rate; Mycobacterium tuberculosis; Naphthyridines; Novobiocin; Piperazines; Terfenadine; Topoisomerase II Inhibitors; Zebrafish; Zebrafish Proteins | 2016 |
Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
Topics: Acridines; Animals; Antitubercular Agents; Bacterial Proteins; Cell Line; Cell Survival; Chlorobenzoates; DNA Gyrase; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Ether-A-Go-Go Potassium Channels; Gene Expression; Heart Rate; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Piperidines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Zebrafish; Zebrafish Proteins | 2016 |
Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Hemolysis; Lysine; Microbial Sensitivity Tests; Minocycline; Models, Biological; Rifampin; Tobramycin | 2017 |
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
Topics: Anti-Bacterial Agents; Cell Survival; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacteria; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniae.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Binding Sites; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Models, Molecular; Molecular Sequence Data; Moxifloxacin; Mutagenesis; Mutagenesis, Site-Directed; Novobiocin; Protein Conformation; Quinolines; Streptococcus pneumoniae | 2003 |